Figure 4.

Kaplan–Meier curves showing the occurrence of post-market safety communications by regulatory review time among medicines approved by the EMA.
, 8–45 weeks;
, 46–54 weeks;
, 55 weeks or more

Kaplan–Meier curves showing the occurrence of post-market safety communications by regulatory review time among medicines approved by the EMA.
, 8–45 weeks;
, 46–54 weeks;
, 55 weeks or more